{"pmid":32296735,"pmcid":"PMC7156160","title":"Prudently conduct the engineering and synthesis of the SARS-CoV-2 virus.","text":["Prudently conduct the engineering and synthesis of the SARS-CoV-2 virus.","Regarding to the recent work of engineering SARS-CoV-19 virus and the publication \"Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform\" by researchers at University of Bern, this paper comments on the \"dual-use\" problem and regulation issue of synthetic biology from the perspective of responsible (research and) innovation, biosafety and biosecurity. Based on the ethical and legal framework, the authors suggest to conduct such research with high potential risks prudently and responsibly.","Synth Syst Biotechnol","Ma, Shiwen","Gao, Peng","Lu, Daru","Wang, Guoyu","32296735"],"abstract":["Regarding to the recent work of engineering SARS-CoV-19 virus and the publication \"Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform\" by researchers at University of Bern, this paper comments on the \"dual-use\" problem and regulation issue of synthetic biology from the perspective of responsible (research and) innovation, biosafety and biosecurity. Based on the ethical and legal framework, the authors suggest to conduct such research with high potential risks prudently and responsibly."],"journal":"Synth Syst Biotechnol","authors":["Ma, Shiwen","Gao, Peng","Lu, Daru","Wang, Guoyu"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296735","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.synbio.2020.03.002","keywords":["Dual-use","Engineering SARS-CoV-2 virus","Regulation","Responsible (research and) innovation","Risk"],"source":"PubMed","weight":0,"_version_":1664266651299741697,"score":8.233237,"similar":[{"pmid":32267678,"title":"COVID-19: A Call for Physical Scientists and Engineers.","text":["COVID-19: A Call for Physical Scientists and Engineers.","The COVID-19 pandemic is one of those global challenges that transcends territorial, political, ideological, religious, cultural, and certainly academic boundaries. Public health and healthcare workers are at the frontline, working to contain and to mitigate the spread of this disease. Although intervening biological and immunological responses against viral infection may seem far from the physical sciences and engineering that typically work with inanimate objects, there actually is much that can-and should-be done to help in this global crisis. In this Perspective, we convert the basics of infectious respiratory diseases and viruses into physical sciences and engineering intuitions, and through this exercise, we present examples of questions, hypotheses, and research needs identified based on clinicians' experiences. We hope researchers in the physical sciences and engineering will proactively study these challenges, develop new hypotheses, define new research areas, and work with biological researchers, healthcare, and public health professionals to create user-centered solutions and to inform the general public, so that we can better address the many challenges associated with the transmission and spread of infectious respiratory diseases.","ACS Nano","Huang, Haiyue","Fan, Chunhai","Li, Min","Nie, Hua-Li","Wang, Fu-Bing","Wang, Hui","Wang, Ruilan","Xia, Jianbo","Zheng, Xin","Zuo, Xiaolei","Huang, Jiaxing","32267678"],"abstract":["The COVID-19 pandemic is one of those global challenges that transcends territorial, political, ideological, religious, cultural, and certainly academic boundaries. Public health and healthcare workers are at the frontline, working to contain and to mitigate the spread of this disease. Although intervening biological and immunological responses against viral infection may seem far from the physical sciences and engineering that typically work with inanimate objects, there actually is much that can-and should-be done to help in this global crisis. In this Perspective, we convert the basics of infectious respiratory diseases and viruses into physical sciences and engineering intuitions, and through this exercise, we present examples of questions, hypotheses, and research needs identified based on clinicians' experiences. We hope researchers in the physical sciences and engineering will proactively study these challenges, develop new hypotheses, define new research areas, and work with biological researchers, healthcare, and public health professionals to create user-centered solutions and to inform the general public, so that we can better address the many challenges associated with the transmission and spread of infectious respiratory diseases."],"journal":"ACS Nano","authors":["Huang, Haiyue","Fan, Chunhai","Li, Min","Nie, Hua-Li","Wang, Fu-Bing","Wang, Hui","Wang, Ruilan","Xia, Jianbo","Zheng, Xin","Zuo, Xiaolei","Huang, Jiaxing"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267678","week":"202015|Apr 06 - Apr 12","doi":"10.1021/acsnano.0c02618","source":"PubMed","weight":0,"_version_":1663609715844710400,"score":85.79834},{"pmid":32250281,"title":"Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","text":["Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support.","JMIR Public Health Surveill","Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P","32250281"],"abstract":["As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support."],"journal":"JMIR Public Health Surveill","authors":["Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250281","week":"202015|Apr 06 - Apr 12","doi":"10.2196/18887","keywords":["COVID-19","clinical research","ethics","infectious disease","outbreak","pandemic","public health"],"source":"PubMed","weight":0,"_version_":1663352136307572736,"score":70.762115},{"pmid":32209231,"pmcid":"PMC7094376","title":"Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus.","text":["Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus.","This paper concerns study of the genome of the Wuhan Seafood Market isolate believed to represent the causative agent of the disease COVID-19. This is to find a short section or sections of viral protein sequence suitable for preliminary design proposal for a peptide synthetic vaccine and a peptidomimetic therapeutic, and to explore some design possibilities. The project was originally directed towards a use case for the Q-UEL language and its implementation in a knowledge management and automated inference system for medicine called the BioIngine, but focus here remains mostly on the virus itself. However, using Q-UEL systems to access relevant and emerging literature, and to interact with standard publically available bioinformatics tools on the Internet, did help quickly identify sequences of amino acids that are well conserved across many coronaviruses including 2019-nCoV. KRSFIEDLLFNKV was found to be particularly well conserved in this study and corresponds to the region around one of the known cleavage sites of the SARS virus that are believed to be required for virus activation for cell entry. This sequence motif and surrounding variations formed the basis for proposing a specific synthetic vaccine epitope and peptidomimetic agent. The work can, nonetheless, be described in traditional bioinformatics terms, and readily reproduced by others, albeit with the caveat that new data and research into 2019-nCoV is emerging and evolving at an explosive pace. Preliminary studies using molecular modeling and docking, and in that context the potential value of certain known herbal extracts, are also described.","Comput Biol Med","Robson, B","32209231"],"abstract":["This paper concerns study of the genome of the Wuhan Seafood Market isolate believed to represent the causative agent of the disease COVID-19. This is to find a short section or sections of viral protein sequence suitable for preliminary design proposal for a peptide synthetic vaccine and a peptidomimetic therapeutic, and to explore some design possibilities. The project was originally directed towards a use case for the Q-UEL language and its implementation in a knowledge management and automated inference system for medicine called the BioIngine, but focus here remains mostly on the virus itself. However, using Q-UEL systems to access relevant and emerging literature, and to interact with standard publically available bioinformatics tools on the Internet, did help quickly identify sequences of amino acids that are well conserved across many coronaviruses including 2019-nCoV. KRSFIEDLLFNKV was found to be particularly well conserved in this study and corresponds to the region around one of the known cleavage sites of the SARS virus that are believed to be required for virus activation for cell entry. This sequence motif and surrounding variations formed the basis for proposing a specific synthetic vaccine epitope and peptidomimetic agent. The work can, nonetheless, be described in traditional bioinformatics terms, and readily reproduced by others, albeit with the caveat that new data and research into 2019-nCoV is emerging and evolving at an explosive pace. Preliminary studies using molecular modeling and docking, and in that context the potential value of certain known herbal extracts, are also described."],"journal":"Comput Biol Med","authors":["Robson, B"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209231","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.compbiomed.2020.103670","keywords":["*2019-nCoV coronavirus","*Automatic browser","*Bioinformatics","*Peptidomimetic","*Q-UEL language","*Retroinverso","*Synthetic vaccine","*Wuhan seafood market coronavirus"],"source":"PubMed","locations":["Q-UEL"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352134904578050,"score":68.85098},{"pmid":32271627,"title":"Self-Isolation Compliance In The COVID-19 Era Influenced By Compensation: Findings From A Recent Survey In Israel.","text":["Self-Isolation Compliance In The COVID-19 Era Influenced By Compensation: Findings From A Recent Survey In Israel.","A new Coronavirus disease (COVID-19) outbreak is spreading since December 2019. In an attempt to contain the disease, health authorities call for self-quarantine of individuals suspected as exposures. Health officials assume the public will comply in high rates; however, studies suggest that a major obstacle to compliance for household quarantine is concern over loss of income. A cross sectional study of the adult population of Israel was conducted in the last week of February 2020 to assess public attitudes toward the COVID-19 outbreak. In particular, public compliance rates with self-quarantine were assessed depending on compensation for lost wages. The results suggest that when compensation was assumed, the compliance rate was 94%; yet, when compensation was removed, the compliance rate dropped to less than 57%. This study demonstrates that providing people with assurances for their livelihood during self-quarantine is an important component in compliance with public health regulations. [Editor's Note: This fast-track Ahead-of-Print article is the accepted version of the peer-reviewed manuscript. The final edited version will appear in an upcoming issue of Health Affairs.].","Health Aff (Millwood)","Bodas, Moran","Peleg, Kobi","32271627"],"abstract":["A new Coronavirus disease (COVID-19) outbreak is spreading since December 2019. In an attempt to contain the disease, health authorities call for self-quarantine of individuals suspected as exposures. Health officials assume the public will comply in high rates; however, studies suggest that a major obstacle to compliance for household quarantine is concern over loss of income. A cross sectional study of the adult population of Israel was conducted in the last week of February 2020 to assess public attitudes toward the COVID-19 outbreak. In particular, public compliance rates with self-quarantine were assessed depending on compensation for lost wages. The results suggest that when compensation was assumed, the compliance rate was 94%; yet, when compensation was removed, the compliance rate dropped to less than 57%. This study demonstrates that providing people with assurances for their livelihood during self-quarantine is an important component in compliance with public health regulations. [Editor's Note: This fast-track Ahead-of-Print article is the accepted version of the peer-reviewed manuscript. The final edited version will appear in an upcoming issue of Health Affairs.]."],"journal":"Health Aff (Millwood)","authors":["Bodas, Moran","Peleg, Kobi"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271627","week":"202015|Apr 06 - Apr 12","doi":"10.1377/hlthaff.2020.00382","keywords":["COVID-19","Compensation","Compliance","Coronavirus","Decision making","Diseases","Emergency medicine","Epidemiology","Global health","Public health","Quarantine","Regulation","Self-quarantine","health policy"],"source":"PubMed","locations":["Israel"],"countries":["Israel"],"countries_codes":["ISR|Israel"],"topics":["Prevention"],"weight":1,"_version_":1663620083118768128,"score":61.737522},{"pmid":32192278,"title":"WHO International Health Regulations Emergency Committee for the COVID-19 outbreak.","text":["WHO International Health Regulations Emergency Committee for the COVID-19 outbreak.","To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). On January 22-23 and January 30, 2020, EC convened and discussed whether the situation in China and other countries would constitute PHEIC and issued recommendations for WHO, China and the international community. Based on the recommendations of EC, WHO declared the COVID-19 outbreak a PHEIC. One of the purposes of the declaration of PHEIC was to alarm countries with weak public health infrastructures to prepare promptly for emerging infectious diseases (EID) and provide WHO with a framework for proactively supporting those countries. On February 3, 2020, WHO proposed the 2019 COVID-19 Strategic Preparedness and Response Plan, which includes accelerating research and development (R&D) processes as one of three major strategies. On February 11-12, 2020, WHO held the Global Research and Innovation Forum: Towards a Research Roadmap for COVID-19. The fact that a COVID-19 R&D forum was the first meeting convened after the PHEIC declaration testifies to the importance of R&D in response to EID. Korea has demonstrated a remarkable capacity in its laboratory response by conducting high-throughput COVID-19 testing and utilizing innovative drive-through samplings. These measures for early detection and screening of cases should be followed by full efforts to produce research-based evidence by thoroughly analyzing epidemiological, clinical and immunological data, which will facilitate the development of vaccines and therapeutics for COVID-19. It is expected that Korea plays a global partner for COVID-19 research by actively participating in immediate and mid/long-term priorities jointly led by WHO and global partners.","Epidemiol Health","Jee, Youngmee","32192278"],"abstract":["To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). On January 22-23 and January 30, 2020, EC convened and discussed whether the situation in China and other countries would constitute PHEIC and issued recommendations for WHO, China and the international community. Based on the recommendations of EC, WHO declared the COVID-19 outbreak a PHEIC. One of the purposes of the declaration of PHEIC was to alarm countries with weak public health infrastructures to prepare promptly for emerging infectious diseases (EID) and provide WHO with a framework for proactively supporting those countries. On February 3, 2020, WHO proposed the 2019 COVID-19 Strategic Preparedness and Response Plan, which includes accelerating research and development (R&D) processes as one of three major strategies. On February 11-12, 2020, WHO held the Global Research and Innovation Forum: Towards a Research Roadmap for COVID-19. The fact that a COVID-19 R&D forum was the first meeting convened after the PHEIC declaration testifies to the importance of R&D in response to EID. Korea has demonstrated a remarkable capacity in its laboratory response by conducting high-throughput COVID-19 testing and utilizing innovative drive-through samplings. These measures for early detection and screening of cases should be followed by full efforts to produce research-based evidence by thoroughly analyzing epidemiological, clinical and immunological data, which will facilitate the development of vaccines and therapeutics for COVID-19. It is expected that Korea plays a global partner for COVID-19 research by actively participating in immediate and mid/long-term priorities jointly led by WHO and global partners."],"journal":"Epidemiol Health","authors":["Jee, Youngmee"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32192278","week":"202012|Mar 16 - Mar 22","doi":"10.4178/epih.e2020013","keywords":["COVID-19","Emergency Committee","International Health Regulations","Public Health Emergency of International Concern","Research and development"],"source":"PubMed","locations":["China","South Korea"],"countries":["Korea, Republic of","China"],"countries_codes":["KOR|Korea, Republic of","CHN|China"],"weight":0,"_version_":1663352133478514688,"score":60.00923}]}